AzTrials
AzTrials

Arthritis of Carpometacarpal Joint of Left ThumbPhase 1NCT06359665

Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) Arthritis

A Phase 1 study testing Curcumin in people with Arthritis of Carpometacarpal Joint of Left Thumb and Arthritis of Carpometacarpal Joint of Right Thumb, run by Brent DeGeorge at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn about the use of turmeric (Curcumin) as a treatment for pain of thumb-joint arthritis. Turmeric is commonly being used as an over-the-counter treatment for musculoskeletal pain. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Curcumin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteUnited States
Study dates
1 Feb 2025to Feb 2026
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged 18 years or older.
  • For females, must be willing to use an approved form of birth control during this study. Acceptable forms of birth control:
  • Norplant
  • IUD (intrauterine device)
Show all 21Show fewer
  • Birth Control Patch
  • Depo-Provera
  • Sterilization
  • The following may be used if combined with other birth control methods:
  • Condoms
  • Diaphragm
  • Jellies or foam
  • Cervical cap
  • Sponge
  • For males, must be willing to not father a baby for the duration of the study and for 90 days after the last dose of study drug, or donate to a sperm back during this time. Must be willing to use an approved form of birth control during this time. Acceptable forms of birth control:
  • Condoms
  • Sterilization
  • Daily visual analog pain greater than 5 and ≤ 9 out of 10.
  • Duration of pain for greater than 30 days.
  • Presence of radiographically confirmed diagnosis of thumb basal joint arthritis

Who cannot join

  • Participant does not speak English.
  • Participant is blind.
  • Severe cardiac, pulmonary, liver, gastrointestinal and hematological disease (including coagulopathy), and /or renal disease.
  • Abnormal hematological, coagulation, and/or liver function test results.
  • Coumadin use at time of screening.
  • Use of any anticoagulant and antiplatelet medication.
Show all 60Show fewer
  • History of mental illness.
  • Participant who is incarcerated.
  • History of drug or substance abuse.
  • Pre-existing curcumin or turmeric product usage within 3 months of the study period.
  • Participant has had a corticosteroid injection ≤ 60 days prior.
  • Participant has had prior surgery for osteoarthritis treatment
  • Participant who has fibromyalgia and post-operative pain.
  • Females who are pregnant, nursing or planning a pregnancy
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP3A4:
  • Itraconazole,
  • Ketoconazole,
  • Azamulin,
  • Troleandomycin,
  • Verapamil,
  • John's wart,
  • Phenobarbital,
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C19:
  • Nootkatone,
  • Ticlopidine,
  • Rifampin,
  • Omeprazole),
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C8:
  • Montelukast,
  • Quercetin,
  • Phenelzine,
  • Rifampin,
  • Clopidogrel ,
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C9:
  • Sulfaphenazole,
  • Tienilic acid,
  • Carbamazepine,
  • Apoflutamide ,
  • Fluconazole,
  • Celecoxib,
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP1A2:
  • alpha-Naphthoflavone,
  • Furafylline,
  • Phenytoin,
  • Rifampin,
  • Ritonavir,
  • smoking,
  • Teriflunomide,
  • Ciprofloxacin,
  • oral contraceptives,
  • Allopurinol
  • Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2B6 :
  • Sertraline,
  • Phencyclidine,
  • Thiotepa,
  • Ticlopidine,
  • Carbamazepine,
  • Efavirenz,
  • Rifampin,
  • Bupropion)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site

  • University of Virginia

    Charlottesville, Virginia, 22903

Other trials in United States

About this study

Official title: A Randomized Controlled Trial of Oral Curcumin for the Treatment of Pain of CMC Arthritis

The goal of this clinical trial is to learn about the use of turmeric (Curcumin) as a treatment for pain of thumb-joint arthritis. Turmeric is commonly being used as an over-the-counter treatment for musculoskeletal pain. Clinical trials have demonstrated a pain-relief benefit for knee osteoarthritis, however no clinical trial has been performed to establish efficacy of curcumin in humans for thumb-joint arthritis. The main question[s] it aims to answer are:

  • Is Turmeric more effective than placebo at relieving pain for thumb-joint arthritis? A placebo is a look-alike substance that contains no active drug.
  • Is Turmeric more effective than placebo at improving patient-reported outcomes for CMC arthritis?
  • Is Turmeric safe for participants with thumb-joint arthritis?
Read more

Participants will:

  • take 4 weeks of daily Turmeric capsules,
  • take 4 weeks of daily placebo capsules
  • answer daily surveys about how they are feeling and functioning.
Read the detailed description

This randomized controlled trial of oral curcumin for the treatment of pain of CMC arthritis will investigate the therapeutic potential of curcumin as an oral treatment for pain of CMC arthritis. Rationale: Curcumin is commonly being used as an over-the-counter treatment for musculoskeletal pain. Clinical trials have demonstrated a pain-relief benefit for knee osteoarthritis, however no clinical trial has been performed to establish efficacy of curcumin in humans for CMC arthritis. Hypothesis: Curcumin is more effective than placebo for relieving pain and improving patient-reported outcomes for CMC arthritis Study Design: The study design will be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 4 weeks of the Curcumin or control and then crossover to the other condition for 4 additional weeks. Patients will take the oral curcumin or control placebo capsule twice daily. Subjects will be advised to observe adverse effects.

The study design will be a double-blind randomized control trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 4 weeks of the case (curcumin) or control capsules and then crossover to the other condition for 4 more weeks with a 2-week washout interval between. Patients will take one oral capsule by mouth twice daily. The subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects. If mild to severe adverse events are noticed, the patient's will discontinue the use of the capsules, and appropriate care and observation will be taken. Each condition will last for 4 weeks and then subjects will be contacted by the study coordinator to facilitate crossover into the other condition following a 2-week washout period. To capture any delayed-onset adverse events, subjects will attend a follow-up visit seven days following the last dose of the curcumin capsule.

Being tested
Curcumin, Placebo
Keywords
Thumb carpometacarpal osteoarthritis (CMC OA), Thumb carpometacarpal Osteoarthritis, turmeric, curcumin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CurcuminDrug

    Also called Nature Made, PharmaVite LLC, Turmeric

    500 mg capsule twice daily

  • PlaceboDrug

    capsule twice daily

Study groups in NCT06359665
Study groupRoleWhat they receive
Oral curcuminExperimentalOral curcumin 500 mg capsules taken twice each day for 4 weeks.
Receives: Drug: Curcumin
PlaceboPlacebo comparatorOral placebo capsules taken twice each day for 4 weeks.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Pain on the Visual Analog Pain (VAS) Score

    The Visual Analog Pain (VAS) Score is a validated, self-reported subjective measure for measuring acute and chronic pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week (4 or 6) Score - Baseline Score).a validated, self-report

    Measured: Baseline and Week 4, Week 6

  2. Change from Baseline in Pain on the Visual Analog Pain (VAS) Score - crossover condition

    The Visual Analog Pain (VAS) Score is a validated, self-reported subjective measure for measuring acute and chronic pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week Change = (Week (10 or 12) Score - Baseline Score).

    Measured: Baseline and Week 10, Week 12

Secondary outcomes (31)

  1. Change from Baseline in Normal Function on the Single Assessment Numerical Evaluation (SANE) Score

    The SANE Score is a self-reported subjective measure for measuring percentage of normal function. Possible scores range from 0 (most abnormal) to 100 (normal). Change = (Week (4 or 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  2. Change from Baseline in Normal Function on the Single Assessment Numerical Evaluation (SANE) Score - crossover condition

    The SANE Score is a self-reported subjective measure for measuring percentage of normal function. Possible scores range from 0 (most abnormal) to 100 (normal). Change = (Week 10, Week 12 Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  3. Change from Baseline in Quality of Life on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 Score

    The PROMIS Global Health-10 is a validated, self-reported subjective measure for measuring generic health related quality of life. Possible scores range from 0 (most severe impairment) to 20 (best health). Change = (Week (4 or 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  4. Change from Baseline in Quality of Life on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 Score - crossover condition

    The PROMIS Global Health-10 is a validated, self-reported subjective measure for measuring generic health related quality of life. Possible scores range from 0 (most severe impairment) to 20 (best health). Change = (Week (10 or 12) Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  5. Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Score

    The PROMIS Pain Interference is a validated, self-reported subjective measure for measuring generic health related quality of life. Possible scores range from 0 (does not interfere) to 10 (completely interferes). Change = (Week (4, 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  6. Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Score - crossover condition

    The PROMIS Pain Interference is a validated, self-reported subjective measure for measuring generic health related quality of life. Possible scores range from 0 (does not interfere) to 10 (completely interferes). Change = (Week (10, 12) Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  7. Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity (UE) Score

    The PROMIS UE computer adaptive test is a validated computer adaptive test to assess upper extremity functional status. Change = (Week (4, 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  8. Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity (UE) Score

    The PROMIS UE computer adaptive test is a validated computer adaptive test to assess upper extremity functional status. Change = (Week (10, 12) Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  9. Change from Baseline in Pain on the Australian/Canadian Hand Osteoarthritis (AUSCAN) Index

    The AUSCAN Index is a 15-item scale measuring pain (5 items), stiffness (1 item) and function (9 items) during the preceding 48 hours. Possible scores range from 0 (none) to 4 (extreme). Change = (Week (4, 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  10. Change from Baseline in Pain on the Australian/Canadian Hand Osteoarthritis (AUSCAN) Index

    The AUSCAN Index is a 15-item scale measuring pain (5 items), stiffness (1 item) and function (9 items) during the preceding 48 hours. Possible scores range from 0 (none) to 4 (extreme). Change = (Week (10, 12) Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  11. Change from Baseline in Disability on The Quick Disability of the Arm, Shoulder (QuickDASH).

    The QuickDASH is a validated, self-reported 11-item scale measuring disability. Possible scores range from 0 (no disability) to 100 (most severe disability. Change = (Week 4 Score - Baseline Score)

    Measured: Baseline and Week 4

  12. Change from Baseline in Disability on The Quick Disability of the Arm, Shoulder (QuickDASH) - crossover condition

    The QuickDASH is a validated, self-reported 11-item scale measuring disability. Possible scores range from 0 (no disability) to 100 (most severe disability. Change = (Week 10 Score - Baseline Score)

    Measured: Baseline and Week 10

  13. Change from Baseline in perseverance on the Brief Resilience Index (BRI)

    The BRI is a validated, self-reported 6-item validated tool to assess for resilience. Possible scores range from 1 (low resilience) to 5 (high resilience). Change = (Week (4, 6) Score - Baseline Score)

    Measured: Baseline and Week 4, Week 6

  14. Change from Baseline in perseverance on the Brief Resilience Index (BRI) - crossover condition

    The BRI is a validated, self-reported 6-item validated tool to assess for resilience. Possible scores range from 1 (low resilience) to 5 (high resilience). Change = (Week (10, 12) Score - Baseline Score)

    Measured: Baseline and Week 10, Week 12

  15. Number of Participants With Treatment-Related Adverse Events

    Treatment-related adverse events will be reported throughout the study by self-report and clinician-driven questions at each visit

    Measured: Through study completion, an average of 12 weeks

  16. Change from Baseline in the Mean Seated Trough Cuff Systolic Blood Pressure

    Blood pressure (SBP and DBP) in mmHg using Sphygmomanometer will be assessed by the researchers at baseline and follow-up

    Measured: Baseline and Week 4

  17. Change from Baseline in heart rate

    Heartbeats per minute (BPM) will be assessed by the researchers at baseline and follow-up

    Measured: Baseline and Week 4

  18. Change from Baseline in the Mean Seated Trough Cuff Systolic Blood Pressure

    Blood pressure (SBP and DBP) in mmHg using Sphygmomanometer will be assessed by the researchers at baseline and follow-up

    Measured: Week 4 and Week 6

  19. Change from Baseline in heart rate

    Heartbeats per minute (BPM) will be assessed by the researchers at baseline and follow-up

    Measured: Week 4 and Week 6

  20. Change from baseline in serum liver panel parameters: Alanine transaminase (ALT), Alkaline phosphatase (ALP) and Aspartate aminotransferase (AST)

    Change from baseline in serum liver panel parameters: ALT, ALP and AST (International units per liter) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  21. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: glucose, blood urea nitrogen (BUN), Creatinine, Calcium

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: glucose, BUN, Creatinine, Calcium (mg/dL) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  22. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: estimated glomerular filtration rate (eGFR)

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: eGFR (mL/min/1.73m2) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  23. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Bilirubin

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Bilirubin (umol/L) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  24. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Sodium, Potassium, Chloride, Carbon Dioxide

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Sodium, Potassium, Chloride, Carbon Dioxide (meq/L) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  25. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Protein, Albumin

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Protein, Albumin (g/dL) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  26. Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Prothrombin time- International normalized ratio (PT-INR)

    Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Prothrombin time- International normalized ratio (PT (seconds)-INR) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  27. Change from baseline in serum complete blood count (CBC) parameters: Red Blood Cells (CBC), White Blood Cells (WBC), Platelets

    Change from baseline in serum complete blood count (CBC) parameters: RBC, WBC, Platelets (uL) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  28. Change from baseline in serum complete blood count (CBC) parameters: Hemoglobin

    Change from baseline in serum complete blood count (CBC) parameters: Hemoglobin (g.dL) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  29. Change from baseline in serum complete blood count (CBC) parameters: Hematocrit

    Change from baseline in serum complete blood count (CBC) parameters: Hematocrit (percentage) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  30. Change from baseline in serum complete blood count (CBC) parameters: Mean Corpuscular Volume (MCV)

    Change from baseline in serum complete blood count (CBC) parameters: Mean Corpuscular Volume (MCV) (pg) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

  31. Change from baseline in serum complete blood count (CBC) parameters: the amount of hemoglobin per red blood cell.(MCH)

    Change from baseline in serum complete blood count (CBC) parameters: the amount of hemoglobin per red blood cell.(MCH) (pg) at baseline and follow up

    Measured: Through study completion, an average of 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Apr 2024
  2. Study start1 Feb 2025
  3. Primary completionFeb 2026 (estimated)
  4. Study completionFeb 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
The study design will be a double-blind, randomized controlled trial with crossover.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06359665
Sponsor's protocol ID
HSR230544
Status last verified
Dec 2025
First submitted
15 Mar 2024
Last updated
19 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wolf JM, Atroshi I, Zhou C, Karlsson J, Englund M. Sick Leave After Surgery for Thumb Carpometacarpal Osteoarthritis: A Population-Based Study. J Hand Surg Am. 2018 May;43(5):439-447. doi: 10.1016/j.jhsa.2017.11.019. Epub 2018 Feb 7.

    PubMed 29428245

  • Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, Fox KP, Knecht DB, McMahill-Walraven CN, Palmer N, Kohane I. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018 Jan 17;360:j5790. doi: 10.1136/bmj.j5790.

    PubMed 29343479

  • Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz RC, Jolad SD, Solyom AM, Kiela PR, Timmermann BN. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 2006 Nov;54(11):3452-64. doi: 10.1002/art.22180.

    PubMed 17075840

  • Lakhan SE, Ford CT, Tepper D. Zingiberaceae extracts for pain: a systematic review and meta-analysis. Nutr J. 2015 May 14;14:50. doi: 10.1186/s12937-015-0038-8.

    PubMed 25972154

  • Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008 Feb 15;75(4):787-809. doi: 10.1016/j.bcp.2007.08.016. Epub 2007 Aug 19.

    PubMed 17900536

  • Daily JW, Yang M, Park S. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Med Food. 2016 Aug;19(8):717-29. doi: 10.1089/jmf.2016.3705.

    PubMed 27533649

  • Travica N, Teasdale S, Marx W. Nutraceuticals in mood disorders: current knowledge and future directions. Curr Opin Psychiatry. 2023 Jan 1;36(1):54-59. doi: 10.1097/YCO.0000000000000826. Epub 2022 Aug 29.

    PubMed 36044293

  • Hafez Ghoran S, Calcaterra A, Abbasi M, Taktaz F, Nieselt K, Babaei E. Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment. Molecules. 2022 Aug 16;27(16):5236. doi: 10.3390/molecules27165236.

    PubMed 36014474

  • Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Front Immunol. 2022 Jul 22;13:891822. doi: 10.3389/fimmu.2022.891822. eCollection 2022.

    PubMed 35935936

  • Bannuru RR, Osani MC, Al-Eid F, Wang C. Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2018 Dec;48(3):416-429. doi: 10.1016/j.semarthrit.2018.03.001. Epub 2018 Mar 10.

    PubMed 29622343

  • Hsiao AF, Lien YC, Tzeng IS, Liu CT, Chou SH, Horng YS. The efficacy of high- and low-dose curcumin in knee osteoarthritis: A systematic review and meta-analysis. Complement Ther Med. 2021 Dec;63:102775. doi: 10.1016/j.ctim.2021.102775. Epub 2021 Sep 16.

    PubMed 34537344

  • Wang Z, Singh A, Jones G, Winzenberg T, Ding C, Chopra A, Das S, Danda D, Laslett L, Antony B. Efficacy and Safety of Turmeric Extracts for the Treatment of Knee Osteoarthritis: a Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Rheumatol Rep. 2021 Jan 28;23(2):11. doi: 10.1007/s11926-020-00975-8.

    PubMed 33511486

  • Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014 Mar 20;9:451-8. doi: 10.2147/CIA.S58535. eCollection 2014.

    PubMed 24672232

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Curcumin in people with Arthritis of Carpometacarpal Joint of Left Thumb and Arthritis of Carpometacarpal Joint of Right Thumb, run by Brent DeGeorge at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 60 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Pain on the Visual Analog Pain (VAS) Score (time frame: Baseline and Week 4, Week 6). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06359665, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in